Cargando…
Genetic Pharmacotherapy as an Early CNS Drug Development Strategy: Testing Glutaminase Inhibition for Schizophrenia Treatment in Adult Mice
Genetic pharmacotherapy is an early drug development strategy for the identification of novel CNS targets in mouse models prior to the development of specific ligands. Here for the first time, we have implemented this strategy to address the potential therapeutic value of a glutamate-based pharmacot...
Autores principales: | Mingote, Susana, Masson, Justine, Gellman, Celia, Thomsen, Gretchen M., Lin, Chyuan-Sheng, Merker, Robert J., Gaisler-Salomon, Inna, Wang, Yvonne, Ernst, Rachel, Hen, René, Rayport, Stephen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705219/ https://www.ncbi.nlm.nih.gov/pubmed/26778975 http://dx.doi.org/10.3389/fnsys.2015.00165 |
Ejemplares similares
-
T220. THE GLUTAMINASE INHIBITOR EBSELEN PREVENTS AMPHETAMINE SENSITIZATION IN MICE
por: Heffetz-Giterman, Lior, et al.
Publicado: (2018) -
Dopamine neuron dependent behaviors mediated by glutamate cotransmission
por: Mingote, Susana, et al.
Publicado: (2017) -
Beyond NMDA Receptors: Homeostasis at the Glutamate Tripartite Synapse and Its Contributions to Cognitive Dysfunction in Schizophrenia
por: Bauminger, Hagar, et al.
Publicado: (2022) -
Current and Emerging Pharmacotherapies for Primary CNS Lymphoma
por: Prodduturi, Prathima, et al.
Publicado: (2012) -
Hippocampal Glutamate NMDA Receptor Loss Tracks Progression in Alzheimer’s Disease: Quantitative Autoradiography in Postmortem Human Brain
por: Kravitz, Efrat, et al.
Publicado: (2013)